Xbrane Biopharma receives FDA approval for Lucamzi biosimilar to Lucentis

Xbrane Biopharma announced the FDA granted approval for Lucamzi, its biosimilar to Lucentis, indicated for retinal disorders including wet age-related macular degeneration.

Detected & updated continuously · Source: Nebula